Clinical Scorecard: ELARA 24-Week Data Show Improvements in Wet AMD and DME
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |
| Key Mechanisms | Flexible dosing of aflibercept 8 mg (Eylea HD) targeting retinal disease activity. |
| Target Population | Patients with prior treatment for wet AMD and DME. |
| Care Setting | Ophthalmology clinics, specifically in a phase 3b clinical trial setting. |
Key Highlights
- Vision gain of up to 3 letters in both wet AMD and DME cohorts.
- Reduction in retinal thickness: approximately 32 µm in AMD and up to 50 µm in DME.
- Patients had prior anti-VEGF treatment but continued to show disease activity.
Guideline-Based Recommendations
Diagnosis
- Assess prior treatment history and current disease activity in wet AMD and DME.
Management
- Implement flexible dosing of aflibercept 8 mg following a treat-and-extend protocol.
Monitoring & Follow-up
- Regular OCT assessments to monitor retinal thickness and disease progression.
Risks
- Consider potential for continued disease activity despite prior anti-VEGF treatments.
Patient & Prescribing Data
Patients with a history of wet AMD or DME requiring ongoing treatment.
Flexible dosing may improve outcomes in patients with prior treatment failures.
Clinical Best Practices
- Utilize OCT for monitoring retinal changes in treated patients.
- Adopt a personalized approach to dosing based on individual patient response.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
